---
title: 'The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade
  glioma: the phase 2 FIREFLY-1 trial'
date: '2023-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37978284/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231118170631&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: BRAF genomic alterations are the most common oncogenic drivers in pediatric
  low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026)
  trial investigated the efficacy of the oral, selective, central nervous system-penetrant,
  type II RAF inhibitor tovorafenib (420 mg m^(-)² once weekly; 600 mg maximum) in
  patients with BRAF-altered, relapsed/refractory pLGG. Arm 2 (n = 60) is an extension
  cohort, which provided treatment access for patients with RAF-altered pLGG after
  ...
disable_comments: true
---
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system-penetrant, type II RAF inhibitor tovorafenib (420 mg m^(-)² once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG. Arm 2 (n = 60) is an extension cohort, which provided treatment access for patients with RAF-altered pLGG after ...